ASH 2013: Idelalisib Shows Strong Response in Indolent Lymphoma
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of PI3K delta for patients with indolent non-Hodgkin's lymphoma refractory to rituximab and to alkylating-agent-containing chemotherapy.
This information was presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans (Abstract #85).
A 'valuable' treatment option
As a single agent, idelalisib achieved an overall response rate of 57 percent in these patients with a median duration of response of 12.5 months.
Idelalisib is a highly selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta. PI3K delta signaling is crucial in the proliferation and survival of B lymphocytes.
Said Ajay Gopal, M.D., Associate Professor, University of Washington School of Medicine and Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle:
It has been more than ten years since a treatment with a novel mechanism of action has been approved for indolent NHL, underscoring the medical need for new treatments for patients who are no longer responsive to currently available therapies. The overall response rate and durability of response observed in this study suggest that idelalisib may become a valuable new therapy for iNHL patients who have very limited treatment options.
Breakthrough treatment
For the study, they enrolled 125 patients with a median age of 64. Confirmed diagnoses included follicular lymphoma (n=72), small lymphocytic lymphoma (n=28), llymphblastic lymphoma/Waldenstrom macroglobulinemia (n=10) and marginal zone lymphoma (n=15). Patients had received a median of four prior treatment regimens, with 79 percent having refractory disease to two or more prior regimens and 90 percent refractory to their most recent regimen.
Gilead submitted a New Drug Application to the Food and Drug Administration for idelalisib in September for the treatment of refractory indolent NHL, and were granted Breakthrough Therapy designation for the compound against chronic lymphocytic leukemia (CLL) in relapsed patients.
Source: Marketwatch
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...
